Immunovant Inc

Immunovant, Inc. is a clinical-stage biopharmaceutical company. The firm focuses on enabling normal lives for patients with autoimmune diseases. It is developing a novel, fully human monoclonal antibody IMVT-1401 that selectively binds to and inhibits the neonatal fragment crystallizable receptor. The company was founded in 2018 and is headquartered in New York, NY.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Immunovant, Inc. is a clinical-stage biopharmaceutical company, which focuses on enabling normal lives for patients with autoimmune diseases. It is developing a novel, fully human monoclonal antibody IMVT-1401 that selectively binds to and inhibits the neonatal fragment crystallizable receptor. The company was founded in 2018 and is headquartered in New York, NY.

LOS ANGELES--(BUSINESS WIRE)---- $IMVT #CLASSACTION--Glancy Prongay & Murray, a Leading Law Firm, Announces Investigation of Immunovant, Inc. f/k/a Health Sciences Acquisitions Corporation (IMVT)

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Immunovant, Inc. f/k/a Health Sciences Acquisitions Corporation (IMVT) on Behalf of Investors

BENSALEM, Pa.--(BUSINESS WIRE)---- $IMVT #CLASSACTION--Law Offices of Howard G. Smith Announces Investigation Immunovant, Inc. f/k/a Health Sciences Acquisitions Corporation (IMVT) on Behalf of Investors

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Immunovant, Inc. f/k/a Health Sciences Acquisitions Corporation (IMVT) on Behalf of Investors

NEW YORK, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a class action lawsuit has been filed against Immunovant, Inc. (f/k/a Health Sciences Acquisitions Corporation (“HSAC”, “Immunovant” or the “Company”) (NASDAQ: IMVT; HSACU; HSAC; and HSACW) in the United States District Court for the Eastern District of New York on behalf of those who purchased or acquired the securities of Immunovant between October 2, 2019 and February 1, 2021, inclusive (the “Class Period”). The lawsuit seeks to recover damages for investors under the federal securities laws.

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Immunovant, Inc. (IMVT)

PHILADELPHIA, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of Immunovant, Inc., f/k/a Health Sciences Acquisitions Corporation, (“Immunovant” or the “Company”) ( NASDAQ: IMVT )  who purchased, or otherwise acquired, IMVT securities between October 2, 2019 and February 1, 2021, both dates inclusive (the “Class Period).

IMVT SHAREHOLDER ALERT - Class Action Filed On Behalf Of Immunovant, Inc. Investors – IMVT Investors Who Have Suffered Losses Greater Than $100,000 Encouraged To Contact Kehoe Law Firm, P.C.

The company is finally getting a break after a rough past couple of weeks.

Why Immunovant Stock Is Bouncing Back Today

Investors didn't respond well to the company's latest quarterly update.

Why Immunovant Stock Dropped Today

New York, New York--(Newsfile Corp. - February 15, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Immunovant, Inc. ("Immunovant" or the "Company") (NASDAQ: IMVT). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Immunovant and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immunovant, Inc. - IMVT

Los Angeles, California--(Newsfile Corp. - February 15, 2021) -  The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Immunovant, Inc. ("Immunovant" or "the Company") (NASDAQ: IMVT) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Immunovant announced a "voluntary pause of dosing in its ongoing clinical trials...

SHAREHOLDER INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Immunovant, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm

Los Angeles, California--(Newsfile Corp. - February 11, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Immunovant, Inc. ("Immunovant" or "the Company") (NASDAQ: IMVT) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Immunovant announced a "voluntary pause of dosing in its ongoing clinical trials...

SHAREHOLDER INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Immunovant, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm

Immunovant (IMVT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Should You Buy Immunovant (IMVT) Ahead of Earnings?

LOS ANGELES--(BUSINESS WIRE)---- $IMVT #IMVT--ONGOING INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Immunovant, Inc.

ONGOING INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Immunovant, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm

Immunovant (IMVT) has been struggling lately, but the selling pressure may be coming to an end soon.

Immunovant (IMVT) Sees Hammer Chart Pattern: Time to Buy?

Los Angeles, California--(Newsfile Corp. - February 7, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Immunovant, Inc. ("Immunovant" or "the Company") (NASDAQ: IMVT) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Immunovant announced a "voluntary pause of dosing in its ongoing clinical trials...

ONGOING INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Immunovant, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm

Los Angeles, California--(Newsfile Corp. - February 6, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Immunovant, Inc. ("Immunovant" or "the Company") (NASDAQ: IMVT) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Immunovant announced a "voluntary pause of dosing in its ongoing clinical trials...

ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Immunovant, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm

Los Angeles, California--(Newsfile Corp. - February 5, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Immunovant, Inc. ("Immunovant" or "the Company") (NASDAQ: IMVT) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Immunovant announced a "voluntary pause of dosing in its ongoing clinical...

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Immunovant, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)---- $IMVT #IMVT--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Immunovant, Inc.

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Immunovant, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm

Shares of biopharmaceutical company Immunovant fell by as much as 47% on Tuesday after the company announced a voluntary pause in its ongoing clinical trials for IMVT-1401, the company's sole experimental candidate, following findings of elevated cholesterol levels in trial participants.  IMVT-1401 is meant to cure thyroid eye disease, also known as Graves' ophthalmopathy.

Immunovant plunges nearly 50% after pausing a trial for its eye drug after unexpected cholesterol finding

Atlanta, Georgia--(Newsfile Corp. - February 2, 2021) - Holzer & Holzer, LLC is investigating whether Immunovant, Inc. (NASDAQ: IMVT) ("Immunovant" or the "Company") complied with federal securities laws. On February 2, 2021, the Company announced it had decided to voluntarily pause dosing in ongoing clinical studies in both Thyroid Eye Disease and Warm Autoimmune Hemolytic Anemia after it had "become aware of a physiological signal consisting of elevated total cholesterol and LDL levels...

SHAREHOLDER ALERT: Investigation of Immunovant Announced by Holzer & Holzer, LLC

Mustang Bio

Phathom Pharmaceuticals

Bionano Genomics

Mustang Bio (NASDAQ: MBIO) shares are trading higher after the company announced the FDA has lifted the clinical hold for its pivotal phase 2 MB-107 clinical trial. The company plans to enroll the first patient in the second quarter of 2021.

Why Mustang Bio, Phathom Pharma And More Are Moving Today

Shares of Immunovant Inc. plunged 49.8% to pace all premarket losers Tuesday, after the biopharmaceutical company said it has paused dosing in its phase 2b trial for IMVT-1401, a treatment for thyroid eye disease (TED). The company said it voluntarily decided to pause dosing, "out of an abundance of caution," after it became aware of a physiological signal consisting of elevated total cholesterol, as cholesterol levels were not measured in prior trials.

Immunovant stock loses half its value after pausing dosing in trial of thyroid eye disease treatment

NEW YORK, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases, today announced a voluntary pause of dosing in its ongoing clinical trials for IMVT-1401.

Immunovant Announces Voluntary Pause in Clinical Dosing of IMVT-1401

Immunovant, Inc. is a clinical-stage biopharmaceutical company focused on monoclonal antibody therapeutic development for autoimmune diseases. Immunovant has a one product pipeline (IMVT-1401) across three clinical phase indications including MG (Phase 2), TED (Phase 2b), and WAIHA (Phase 2a).

Immunovant: IMVT-1401's Indication Expansion, $444M In Cash And New Management

NEW YORK, Jan. 12, 2021 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases, today announced the appointment of Rita Jain, M.D. as Chief Medical Officer. Dr. Jain brings over 20 years of drug development and biopharmaceutical leadership experience to Immunovant, including industry-leading experience in both early and late phase development.

Immunovant Appoints Rita Jain Chief Medical Officer And Provides Corporate Update

AdaptHealth Corp

Betterware de Mexico

DraftKings

Iridium Communications

Open Lending Corp

MP Materials

QuantumScape

Repay Holdings Corp

Switchback Energy Acquisition Corp

There has been plenty of completed SPAC merger news in 2020 as more companies use it to go public and we're looking at the top performers. The post Completed SPAC Mergers 2020: 10 Top Performing SPACs of the Year appeared first on InvestorPlace.

Completed SPAC Mergers 2020: 10 Top Performing SPACs of the Year

Company Ended the Quarter With Cash of Approximately $444 Million Company Ended the Quarter With Cash of Approximately $444 Million

News for Immunovant Inc Stock (IMVT)